[{"id":"33977d21-22a6-4470-b1db-190f3e51c0f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04094766","created_at":"2021-01-18T20:02:08.891Z","updated_at":"2024-07-02T16:36:39.051Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia","source_id_and_acronym":"NCT04094766","lead_sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LB1909"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2017","start_date":" 08/01/2017","primary_txt":" Primary completion: 08/30/2020","primary_completion_date":" 08/30/2020","study_txt":" Completion: 08/30/2020","study_completion_date":" 08/30/2020","last_update_posted":"2020-11-05"}]